Regeneron Pharmaceuticals has announced plans to acquire the assets of 23andMe for $256 million, following the genetic testing company's Chapter 11 bankruptcy filing in March 2025. The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services, and its extensive biobank containing genetic data from over 15 million individuals. Notably, the deal excludes 23andMe's telehealth division, Lemonaid Health.
Once valued at $6 billion after its 2021 public debut, 23andMe faced significant challenges, including a $30 million settlement over a data breach affecting nearly 7 million users and mounting financial losses. These issues culminated in the company's bankruptcy filing and the resignation of co-founder and CEO Anne Wojcicki.
Regeneron has pledged to uphold 23andMe's existing privacy policies and comply with all applicable laws concerning customer data. A court-appointed ombudsman will oversee the ethical handling of the genetic information. The acquisition aims to enhance Regeneron's capabilities in genomics-driven drug discovery while maintaining uninterrupted consumer genome services.
Stay Informed with Workplay
In an era where data privacy and biotechnology intersect, staying informed is crucial. Workplay provides timely updates and insights on significant developments like the Regeneron-23andMe acquisition, helping you navigate the evolving landscape of health and technology.